|11 January 2017|
A pioneering new biomedical facility in London is to play a major role in the battle against cancer.
Imperial College London’s biomedical research facility is to receive over $24 million of UK Government funding to bring leading scientists, engineers and clinicians together to collaborate and find solutions to some of the world’s most pressing health problems. It will be based in the Michael Uren Biomedical Engineering Research Hub, a research building funded by a $50 million donation from Sir Michael Uren OBE, an Imperial alumnus.
Imperial College London’s President Alice P. Gast said: “The facility, and its world-leading research, will be an epicentre of biomedical engineering innovation.”
The Imperial College Biomedical Engineering Hub will target the development of game-changing tech designed to overcome a variety of biomedical and medical challenges, including the early detection, monitoring and treatment of cancer.
In an article on Imperial’s news pages, Professor Anthony Bull – co-director of the multidisciplinary Biomedical Engineering Hub – said: “The College is renowned for its pioneering advances in medical technology. We know this can only be achieved by drawing expertise across disciplinary boundaries. We cannot work in silos. This funding will allow us to take a great leap forward by bringing together a critical mass of engineers, scientists, and clinicians on an unprecedented scale. The opportunities this presents are tremendous.”